SMT201900218T1 - Composti organici di monobattami, per il trattamento di infezioni batteriche - Google Patents

Composti organici di monobattami, per il trattamento di infezioni batteriche

Info

Publication number
SMT201900218T1
SMT201900218T1 SM20190218T SMT201900218T SMT201900218T1 SM T201900218 T1 SMT201900218 T1 SM T201900218T1 SM 20190218 T SM20190218 T SM 20190218T SM T201900218 T SMT201900218 T SM T201900218T SM T201900218 T1 SMT201900218 T1 SM T201900218T1
Authority
SM
San Marino
Prior art keywords
treatment
organic compounds
bacterial infections
monobactam
monobactam organic
Prior art date
Application number
SM20190218T
Other languages
English (en)
Italian (it)
Inventor
Virender Singh Aulakh
Anthony Casarez
Xiaodong Lin
Mika Lindvall
Glenn Mcenroe
Heinz Ernst Moser
Folkert Reck
Meiliana Tjandra
Robert Lowell Simmons
Aregahegn Yifru
Qingming Zhu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SMT201900218T1 publication Critical patent/SMT201900218T1/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20190218T 2014-03-24 2015-03-23 Composti organici di monobattami, per il trattamento di infezioni batteriche SMT201900218T1 (it)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461969735P 2014-03-24 2014-03-24
US201462088304P 2014-12-05 2014-12-05
PCT/US2015/022011 WO2015148379A1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections
EP15714147.4A EP3122745B1 (en) 2014-03-24 2015-03-23 Monobactam organic compounds for the treatment of bacterial infections

Publications (1)

Publication Number Publication Date
SMT201900218T1 true SMT201900218T1 (it) 2019-05-10

Family

ID=52808201

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20190218T SMT201900218T1 (it) 2014-03-24 2015-03-23 Composti organici di monobattami, per il trattamento di infezioni batteriche

Country Status (37)

Country Link
US (4) US9174978B2 (OSRAM)
EP (2) EP3511328B1 (OSRAM)
JP (1) JP6153674B2 (OSRAM)
KR (1) KR101733441B1 (OSRAM)
CN (1) CN106164072B (OSRAM)
AP (1) AP2016009374A0 (OSRAM)
AU (1) AU2015236369B2 (OSRAM)
BR (1) BR112016020333B1 (OSRAM)
CA (1) CA2939254C (OSRAM)
CL (1) CL2016002285A1 (OSRAM)
CU (1) CU24441B1 (OSRAM)
CY (1) CY1121701T1 (OSRAM)
DK (2) DK3122745T3 (OSRAM)
EA (1) EA030850B1 (OSRAM)
EC (1) ECSP16073620A (OSRAM)
ES (2) ES2862203T3 (OSRAM)
GT (1) GT201600183A (OSRAM)
HR (1) HRP20190501T1 (OSRAM)
HU (1) HUE042134T2 (OSRAM)
IL (1) IL247259B (OSRAM)
LT (1) LT3122745T (OSRAM)
MA (1) MA39777B1 (OSRAM)
MX (1) MX373444B (OSRAM)
MY (1) MY179292A (OSRAM)
PE (1) PE20161371A1 (OSRAM)
PH (1) PH12016501577B1 (OSRAM)
PL (1) PL3122745T3 (OSRAM)
PT (1) PT3122745T (OSRAM)
RS (1) RS58509B1 (OSRAM)
SG (1) SG11201606711UA (OSRAM)
SI (1) SI3122745T1 (OSRAM)
SM (1) SMT201900218T1 (OSRAM)
SV (1) SV2016005274A (OSRAM)
TW (1) TWI714525B (OSRAM)
UA (1) UA121383C2 (OSRAM)
WO (1) WO2015148379A1 (OSRAM)
ZA (1) ZA201605565B (OSRAM)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092620A1 (ru) * 2015-09-23 2021-06-30 Новартис Аг Соли и твердые формы монобактамного антибиотика
WO2017081615A1 (en) 2015-11-09 2017-05-18 Wockhardt Limited 7-oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections
CA3008006C (en) 2015-12-15 2024-04-09 Merck Sharp & Dohme Corp. Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
KR102408800B1 (ko) 2016-03-07 2022-06-13 머크 샤프 앤드 돔 코포레이션 비시클릭 아릴 모노박탐 화합물 및 박테리아 감염의 치료를 위한 그의 사용 방법
ES2966369T3 (es) 2017-03-20 2024-04-22 Broad Inst Inc Compuestos y métodos para el tratamiento de enfermedades parasitarias
CN111094281B (zh) * 2017-08-02 2023-08-29 诺华股份有限公司 用于制备单内酰胺抗生素的化学方法及其中间体
WO2019058346A1 (en) * 2017-09-22 2019-03-28 Novartis Ag MONOBACTAM ADMINISTRATION IN ASSOCIATION WITH ANTIBIOTIC AGENT FOR THE TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION
SG11202002575UA (en) 2017-10-02 2020-04-29 Merck Sharp & Dohme Chromane monobactam compounds for the treatment of bacterial infections
SG11202002300QA (en) * 2017-10-02 2020-04-29 Arixa Pharmaceuticals Inc Aztreonam derivatives and uses thereof
WO2019092180A1 (en) * 2017-11-10 2019-05-16 Novartis Ag Administration of monobactam for the treatment of urinary tract infection
US11459323B2 (en) 2018-01-29 2022-10-04 Medshine Discovery Inc. Monocyclic β-lactam compound for treating bacterial infection
KR102017784B1 (ko) * 2018-04-11 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 검출용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
KR102017785B1 (ko) * 2018-05-17 2019-09-03 전북대학교산학협력단 민감성 및 선택성을 개선한 캠필로박터 선택증균용 배지 조성물 및 이를 이용한 캠필로박터 검출방법
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
IL280770B2 (en) 2018-08-09 2024-05-01 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
TW202024068A (zh) 2018-11-13 2020-07-01 大陸商南京聖和藥業股份有限公司 單環內醯胺化合物及其應用
JP7179185B2 (ja) * 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β-ラクタム化合物の使用
KR102786898B1 (ko) * 2019-11-22 2025-03-25 쑤저우 얼예 파마슈티칼 컴퍼니 리미티드 설포닐우레아 고리 치환 모노시클릭 β-락탐계 항생제
CN111303144B (zh) * 2019-12-13 2020-11-27 苏州信诺维医药科技有限公司 一种治疗细菌感染的化合物
US12491180B2 (en) 2019-12-19 2025-12-09 Shenzhen Optimum Biological Technology Co., Ltd Application of compound in treating pneumonia
EP3838266A1 (en) 2019-12-20 2021-06-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Microfluidic production of biofunctionalized giant unilamellar vesicles for targeted intracellular cargo delivery
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
EP4165039B1 (en) * 2020-07-16 2024-08-21 Ningxia Academy of Agriculture and Forestry Sciences Novel monobactam compounds, their preparation and use as antibacterial agents
WO2022185240A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Formulation of a monobactam antibiotic
WO2022185241A1 (en) 2021-03-04 2022-09-09 Bp Asset Vi, Inc. Process for manufacturing a monobactam antibiotic
KR20240105442A (ko) 2021-11-18 2024-07-05 머크 샤프 앤드 돔 엘엘씨 크로만 아미딘 모노박탐 항생제
CN115304594B (zh) 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ196202A (en) 1980-02-07 1984-07-31 Squibb & Sons Inc Beta-lactam antibiotics (of azetidine-sulphonic acid type)
US4775670A (en) 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
EP0048953B1 (en) 1980-09-29 1988-03-09 E.R. Squibb & Sons, Inc. Beta-lactam antibiotics
WO1982001873A1 (en) * 1980-12-05 1982-06-10 Takeda Chemical Industries Ltd 1-sulfo-2-oxoazetidine derivatives and process for their preparation
JPS58210061A (ja) * 1982-05-31 1983-12-07 Takeda Chem Ind Ltd 1−スルホ−2−オキソアゼチジン誘導体、その製造法および用途
US4782147A (en) * 1980-12-05 1988-11-01 Takeda Chemical Industries, Ltd. 1-sulfo-2-oxoazetidine derivatives and their production
JPS58189176A (ja) * 1982-04-30 1983-11-04 Takeda Chem Ind Ltd 1−スルホ−2−アゼチジノン誘導体およびその製造法
CA1262128A (en) 1981-08-27 1989-10-03 Christian N. Hubschwerlen .beta.-lactams
IL67451A (en) 1981-12-25 1987-10-20 Takeda Chemical Industries Ltd 4-cyano-2-azetidinones and production thereof and process for the preparation of 4-carbamoyl-2-azetidinones using them
GB2116183B (en) 1982-03-03 1985-06-05 Genentech Inc Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
AU564150B2 (en) * 1982-04-30 1987-08-06 Takeda Chemical Industries Ltd. 1-sulfo-2-azetidinone derivatives
HU189290B (en) 1982-05-31 1986-06-30 Banyu Pharmaceutical Co Ltd,Jp Process for preparing new 2-oxo-1-azetidine-sulphonic acid derivatives and pharmaceutically acceptable salts thereof, further pharmaceutical compositions containing such derivatives as active substances
EP0096297B1 (de) 1982-06-03 1988-06-15 F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft Verfahren zur Herstellung von 1-Sulfo-2-oxoazetidinderivaten
JPS6153282A (ja) 1984-08-22 1986-03-17 Banyu Pharmaceut Co Ltd 単環β−ラクタム誘導体
JPS6153283A (ja) 1984-08-24 1986-03-17 Banyu Pharmaceut Co Ltd 2−オキソ−1−アゼチジンスルホン酸誘導体
US4610824A (en) 1984-10-09 1986-09-09 E. R. Squibb & Sons, Inc. Hydrazide derivatives of monocyclic beta-lactam antibiotics
US5112968A (en) 1989-07-28 1992-05-12 E. R. Squibb & Sons, Inc. Monobactam hydrazide derivatives
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
DE69738749D1 (de) 1996-08-16 2008-07-17 Schering Corp Zelloberflächen-antigen aus säugetieren und verwandte reagenzien
JP2001520039A (ja) 1997-10-21 2001-10-30 ヒューマン ジノーム サイエンシーズ, インコーポレイテッド ヒト腫瘍壊死因子レセプター様タンパク質、tr11,tr11sv1およびtr11sv2
WO1999040196A1 (en) 1998-02-09 1999-08-12 Genentech, Inc. Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
ES2295040T3 (es) 1999-07-12 2008-04-16 Genentech, Inc. Promocion o inhibicion de la angiogenesis y cardiovascularizacion mediante homologos del ligando / receptor del factor de necrosis del tumor.
BR0316880A (pt) 2002-12-23 2005-10-25 Wyeth Corp Anticorpos contra pd-1 e usos dos mesmos
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
US7618632B2 (en) 2003-05-23 2009-11-17 Wyeth Method of treating or ameliorating an immune cell associated pathology using GITR ligand antibodies
EP1660126A1 (en) 2003-07-11 2006-05-31 Schering Corporation Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
WO2005055808A2 (en) 2003-12-02 2005-06-23 Genzyme Corporation Compositions and methods to diagnose and treat lung cancer
GB0409799D0 (en) 2004-04-30 2004-06-09 Isis Innovation Method of generating improved immune response
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
CA2602777C (en) 2005-03-25 2018-12-11 Tolerrx, Inc. Gitr binding molecules and uses therefor
EP2439273B1 (en) 2005-05-09 2019-02-27 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
US20110212086A1 (en) 2006-01-19 2011-09-01 Genzyme Corporation GITR Antibodies For The Treatment of Cancer
EP2069347A2 (en) 2006-09-27 2009-06-17 Merck & Co., Inc. Novel inhibitors of beta-lactamase
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
DK2175884T3 (en) 2007-07-12 2016-09-26 Gitr Inc Combination USING GITR BINDING MOLECULES
DK2231667T3 (da) 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US20110177070A1 (en) 2008-07-02 2011-07-21 Emergent Product Development Seatlle, LLC TGF-Beta Antagonist Multi-Target Binding Proteins
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX2011002250A (es) 2008-08-25 2011-08-17 Amplimmune Inc Antagonistas de muerte celular programada-1 y métodos de uso de los mismos.
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
US8586023B2 (en) 2008-09-12 2013-11-19 Mie University Cell capable of expressing exogenous GITR ligand
KR101655961B1 (ko) 2008-10-31 2016-09-08 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
US20120053350A1 (en) 2009-04-30 2012-03-01 Ian Mangion Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
SG178991A1 (en) 2009-09-03 2012-04-27 Schering Corp Anti-gitr antibodies
GB0919054D0 (en) 2009-10-30 2009-12-16 Isis Innovation Treatment of obesity
WO2011061760A1 (en) 2009-11-18 2011-05-26 Cadila Healthcare Limited Novel antithrombotic agents
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Pd−l1/pd−l2の同時阻害
PT2519543T (pt) 2009-12-29 2016-10-07 Emergent Product Dev Seattle Proteínas de ligação de heterodímero e suas utilizações
JP2012027846A (ja) 2010-07-27 2012-02-09 Sony Corp 情報処理装置、情報表示方法及びコンピュータプログラム
DK2646436T3 (en) 2010-11-29 2015-06-29 Pfizer monobactams
PL2748151T3 (pl) 2011-08-25 2016-09-30 Pirymidynowe inhibitory pde10
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
WO2013039954A1 (en) 2011-09-14 2013-03-21 Sanofi Anti-gitr antibodies
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
EP2814483A2 (en) 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
AU2013308127B2 (en) 2012-08-25 2015-08-13 Wockhardt Limited 1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
CN103044416A (zh) 2012-12-17 2013-04-17 浙江华方药业有限责任公司 一种卡芦莫南钠的合成方法
WO2014141132A1 (en) 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
US20160326157A1 (en) 2014-01-06 2016-11-10 President And Fellows Of Harvard College Monobactams and methods of their synthesis and use

Also Published As

Publication number Publication date
CA2939254C (en) 2023-02-14
US10369138B2 (en) 2019-08-06
MA39777B1 (fr) 2019-03-29
EP3122745A1 (en) 2017-02-01
UA121383C2 (uk) 2020-05-25
JP2017510580A (ja) 2017-04-13
ES2862203T3 (es) 2021-10-07
PH12016501577B1 (en) 2022-04-29
SV2016005274A (es) 2018-06-12
BR112016020333B1 (pt) 2022-08-09
PH12016501577A1 (en) 2016-10-03
IL247259A0 (en) 2016-09-29
CN106164072B (zh) 2019-10-01
ECSP16073620A (es) 2018-12-31
AP2016009374A0 (en) 2016-08-31
PE20161371A1 (es) 2016-12-21
KR101733441B1 (ko) 2017-05-10
CL2016002285A1 (es) 2016-12-30
EP3511328A1 (en) 2019-07-17
ZA201605565B (en) 2017-09-27
WO2015148379A1 (en) 2015-10-01
ES2719136T3 (es) 2019-07-08
US20160051523A1 (en) 2016-02-25
IL247259B (en) 2020-02-27
MX2016011822A (es) 2016-12-02
PL3122745T3 (pl) 2019-08-30
KR20160110541A (ko) 2016-09-21
DK3511328T3 (da) 2021-03-22
MY179292A (en) 2020-11-03
CU24441B1 (es) 2019-09-04
HUE042134T2 (hu) 2019-06-28
CN106164072A (zh) 2016-11-23
SI3122745T1 (sl) 2019-05-31
US9174978B2 (en) 2015-11-03
NZ723114A (en) 2020-12-18
MA39777A (fr) 2017-02-01
JP6153674B2 (ja) 2017-06-28
EA030850B1 (ru) 2018-10-31
RS58509B1 (sr) 2019-04-30
AU2015236369B2 (en) 2017-02-16
CA2939254A1 (en) 2015-10-01
HRP20190501T1 (hr) 2019-05-03
CY1121701T1 (el) 2020-07-31
MX373444B (es) 2020-04-30
CU20160131A7 (es) 2017-02-02
EA201691766A1 (ru) 2016-12-30
PT3122745T (pt) 2019-04-30
AU2015236369A1 (en) 2016-09-01
US20190231752A1 (en) 2019-08-01
TW201540712A (zh) 2015-11-01
BR112016020333A2 (pt) 2017-10-24
EP3511328B1 (en) 2021-03-03
US20150266867A1 (en) 2015-09-24
EP3122745B1 (en) 2019-02-27
SG11201606711UA (en) 2016-10-28
US20200276169A1 (en) 2020-09-03
TWI714525B (zh) 2021-01-01
GT201600183A (es) 2018-12-18
LT3122745T (lt) 2019-04-10
DK3122745T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
IL247259A0 (en) Organic monobactam compounds for the treatment of bacterial infections
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
ZA202001721B (en) Chromane monobactam compounds for the treatment of bacterial infections
EP3125893A4 (en) Organic compounds
EP3125892A4 (en) Organic compounds
EP3157565A4 (en) Treatment of polybacterials infections
ZA201703245B (en) Combination therapy for treatment of resistant bacterial infections
EP3226862A4 (en) Organic compounds
EP3177627A4 (en) Organic compounds
EP3157926A4 (en) Organic compounds
EP3091982A4 (en) Organic compounds
EP3226870A4 (en) Organic compounds
IL249616A0 (en) Methods for treating inflammation
AU2014901912A0 (en) Compounds for the treatment of bacterial infections
AU2014901885A0 (en) Compounds for the treatment of antibacterial infections
ZA201704589B (en) Compounds for the treatment of cancer
TH1501004125A (th) สารประกอบและวิธีการสำหรับการรักษาการติดเชื้อแบคทีเรีย
GB201404621D0 (en) Organic transistors
GB201401087D0 (en) Organic compounds